Acute skeletal muscle atrophy in AP-injected HSA-Fv2E-PERK Tg mice.

(A) Body weight (BW) curves of AP-injected wild-type (WT) male, vehicle-injected HSA-Fv2E-PERK Tg mice, and AP-injected HSA-Fv2E-PERK Tg mice; vehicle or AP (0.1 mg/kg BW) were injected intraperitoneally once a day for 7 days (n = 5). (B) BW changes are expressed as percentages of initial BWs (Fig 2A). (C) Muscle weights of the extensor digitorum longus (EDL), tibialis anterior (TA), gastrocnemius (GC), and soleus (Sol) muscles of AP-injected WT, vehicle-injected Tg and AP-injected Tg mice; vehicle or AP (0.1 mg/kg BW) were intraperitoneally injected once a day for 7 days (n = 5). (D) Representative hematoxylin and eosin (H&E) staining of TA muscles of WT and HSA-Fv2E-PERK Tg mice. Vehicle or AP (0.1 mg/kg BW) was intraperitoneally injected once a day for 7 days. Right graph shows relative muscle cross-sectional area (CSA) of each genotype. Differences among AP-treated HSA-Fv2E-PERK Tg mice, vehicle-treated HSA-Fv2E-PERK Tg mice, and AP-treated WT mice treated were considered significant at *p < 0.05 or **p < 0.01.